GenomeWeb: Pacific Edge Bladder Cancer Recurrence Test Outperforms Others in Head-to-Head Comparison
by Elizabeth Newbern NEW YORK (GenomeWeb) – A recently published study by researchers from New Zealand-based diagnostic firm Pacific Edge and collaborators has shown that the firm's... read more
404: New Opencart News Page
Site Map
Cxbladder Test Suite Adopted by MidCentral DHB
Pacific Edge Signs Agreement Extending Commercial Partnership with MidCentral District Health Board, to Encompass All Cxbladder Tests for Application Across the Clinical Pathway Cancer diagnostics company, Pacific... read more
2018
Pacific Edge Signs First Commercial Agreement in Singapore
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has reached a commercial agreement with Raffles Diagnostica Pte Ltd to offer its suite of Cxbladder tests in Singapore. Under... read more
Another New Zealand Public Healthcare Provider Signs Up to Cxbladder
Counties Manukau Health to Adopt Cxbladder Tests for Application Across the Clinical Pathway Cancer diagnostics company Pacific Edge (NZX: PEB) has received notification from Counties Manukau District... read more
Clinical Publications
Harvey JC, Fletcher D, Ellen CW, Colonval M, Hazlett JA, Zhou X, Newell JM. *Analytical Validation of the Cxbladder® Triage Plus Assay for Risk Stratification of... read more
Cxbladder Commercial Evaluation by Johns Hopkins Medicine
Cancer diagnostics company, Pacific Edge, advises that Johns Hopkins Medicine has commenced their commercial evaluation of Cxbladder, the company’s non-invasive molecular diagnostic test for the detection... read more
Full Suite of Cxbladder Tests Adopted by NZ Public Healthcare Provider Capital & Coast DHB
Cancer diagnostics company, Pacific Edge (NZX: PEB), has entered into an agreement with one of New Zealand’s largest public healthcare providers, Capital & Coast District Health... read more